Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the target of a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 394,950 shares, a decrease of 18.3% from the February 26th total of 483,655 shares. Based on an average trading volume of 102,973 shares, the days-to-cover ratio is currently 3.8 days. Approximately 2.6% of the company’s shares are short sold.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on SRTS shares. Maxim Group decreased their price target on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Wall Street Zen lowered shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Alliance Global Partners initiated coverage on shares of Sensus Healthcare in a report on Friday, March 6th. They issued a “buy” rating and a $7.50 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.88.

Sensus Healthcare Stock Down 1.8%

SRTS stock traded down $0.07 during trading on Monday, hitting $3.85. 11,308 shares of the company’s stock traded hands, compared to its average volume of 93,898. The firm has a market capitalization of $63.40 million, a P/E ratio of -8.19 and a beta of 1.22. Sensus Healthcare has a 1 year low of $3.03 and a 1 year high of $5.92. The business has a fifty day simple moving average of $4.41 and a two-hundred day simple moving average of $3.98.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.10). Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.The firm had revenue of $4.94 million during the quarter, compared to analysts’ expectations of $8.35 million. On average, equities research analysts predict that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Opes Wealth Management LLC acquired a new stake in Sensus Healthcare during the third quarter worth about $50,000. XTX Topco Ltd purchased a new position in shares of Sensus Healthcare during the 4th quarter valued at approximately $77,000. Jane Street Group LLC acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at $79,000. Mindset Wealth Management LLC boosted its holdings in Sensus Healthcare by 28.1% during the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after buying an additional 11,000 shares in the last quarter. Finally, Ingalls & Snyder LLC acquired a new stake in Sensus Healthcare during the fourth quarter valued at $219,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.